Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT).

Abstract

The Journal of Gene MedicineVolume 5, Issue 3 p. 261-262 Position Statement Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) Position of the European Society of Gene Therapy (ESGT) Bernd Gansbacher, Corresponding Author Bernd Gansbacher President ESGT Central Office Institutür Experimentelle Onkologie und Therapieforschung Technische Universität München Ismaninger Str. 22 81675 Munich, GermanyESGT Central Office Institutür Experimentelle Onkologie und Therapieforschung Technische Universität München Ismaninger Str. 22 81675 Munich, GermanySearch for more papers by this author Bernd Gansbacher, Corresponding Author Bernd Gansbacher President ESGT Central Office Institutür Experimentelle Onkologie und Therapieforschung Technische Universität München Ismaninger Str. 22 81675 Munich, GermanyESGT Central Office Institutür Experimentelle Onkologie und Therapieforschung Technische Universität München Ismaninger Str. 22 81675 Munich, GermanySearch for more papers by this author First published: 21 March 2003 https://doi.org/10.1002/jgm.390Citations: 35Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume5, Issue3March 2003Pages 261-262 RelatedInformation